The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Open accessAbstract
Background Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment.Objective This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain.Design Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28-43], 729 subjects lost > or =8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase.Results After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 +/- 4.5% compared with 58.7 +/- 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained < or = 25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001).Conclusion The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is also evidence that antiobesity medications, including long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, naltrexone/bupropion, phentermine/topiramate, and orlistat, may help maintenance of achieved weight reduction.5,7,8,9,10,11,12”
From Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 27,137
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,453
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Energy and protein requirements*
Pacey, A., & Payne, P. (2019) · Routledge eBooks · doi:10.4324/9780429036279-4 · Cited by 2,545
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Statistical Principles in Experimental Design.
Geisser, S., & Winer, B. J. (1963) · Journal of the American Statistical Association · doi:10.2307/2283359 · Cited by 1,934
(1998) · PubMed · Cited by 1,259
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Beneficial health effects of modest weight loss.
Goldstein, D. J. (1992) · PubMed · Cited by 915
American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart Disease
Eckel, R. H., & Krauss, R. M. (1998) · Circulation · doi:10.1161/01.cir.97.21.2099 · Cited by 807
Research works printed but not linked: 1
- 1985, Energy and protein requirement. Report of a joint FAO/WHO/UNU Expert Consultation, World Health Organ Tech Rep Ser, 724
Cited by
Sorted by citations
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It
The Look AHEAD Research Group (2006) · Obesity · doi:10.1038/oby.2006.84 · Cited by 873
“This is because previous studies found that the addition of medication did not significantly increase weight loss after an initial loss of 10% (66,67).”
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Dombrowski, S. U., Knittle, K., Avenell, A., Araujo-Soares, V., & Sniehotta, F. F. (2014) · BMJ · doi:10.1136/bmj.g2646 · Cited by 816
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Self-citationAronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860
Self-citationMeta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
“Study, Year (Reference) Medication Quality Score† Population Co-Interventions Arm Intervention Patients Who Entered Study/Patients Who Completed Study, n/n Mean Weight Change ± SD Follow-up, mo Naumov et al., 2002 (65) Orlistat 1 Adults Low-fat diet, no caloric restriction 1 Control, dosage and duration NR 15/15 2.9 3…”
BackgroundInfluentialBehavioral treatment of obesity
Butryn, M. L., Webb, V., & Wadden, T. A. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.006 · Cited by 636
McTigue, K. M., Harris, R., Hemphill, B., Lux, L. J., Sutton, S. F., Bunton, A. J., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00013 · Cited by 599
“…al., 2000 (93) 120 mg tid D All participants: Dietary advice ( 600 kcal/d) individualized advice throughout the 1-y loss phase 96 NR 82 43 35.9 kg/m2 Hill et al., 1999 (92) 30, 60, or 120 mg 3 times daily D, E, B All participants: 4180-kJ/d deficit diet Multivitamin 729 White: 88 Black: 6…”
BackgroundInfluentialObesity: Responding to the global epidemic.
Wadden, T. A., Brownell, K. D., & Foster, G. D. (2002) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.70.3.510 · Cited by 615
“In particular, medications could help facilitate the maintenance of weight loss if patients took them long-term, in the same manner that antihypertensive or antidiabetic agents are taken (Hill et al., 1999; Stunkard, 1982).”
BackgroundOrlistat, a New Lipase Inhibitor for the Management of Obesity
Heck, A. M., Yanovski, J. A., & Calis, K. A. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.4.270.34882 · Cited by 576
“The utility of orlistat for weight maintenance after conventional dieting was examined in a 1year study of obese subjects who were able to lose 8% or more of their initial body weight with a 6-month hypocaloric diet.(31) During the 6month weight-reduction period, 1313 otherwise healthy obese subjects (BMI 28–43 kg/m(2…”
MethodYanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 555
One-year weight losses in the Look AHEAD study: factors associated with success
Wadden, T. A., West, D. S., Neiberg, R. H., Wing, R. R., Ryan, D. H., Johnson, K. C., Foreyt, J. P., Hill, J. O., Trence, D. L., Vitolins, M. Z., et al. (2009) · Obesity · doi:10.1038/oby.2008.637 · Cited by 525
“In addition to problem solving (26) and motivational interviewing approaches (27,28), the toolbox included the weight loss medication, orlistat (29,30).”
BackgroundSelf-citationShekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttorp, M. J., Rhodes, S. L., Jungvig, L., & Gagné, J. (2003) · JAMA · doi:10.1001/jama.289.12.1537 · Cited by 511
“Molnar et al,27 2000 4 Ephedrine (30-60) and caffeine (100 for 1 wk) 20 wk 16 16 0.”
InfluentialInhibitory Effects of Oolong Tea Polyphenols on Pancreatic Lipase in Vitro
Nakai, M., Fukui, Y., Asami, S., Toyoda‐Ono, Y., Iwashita, T., Shibata, H., Mitsunaga, T., Hashimoto, F., & Kiso, Y. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf047814+ · Cited by 493
LeBlanc, E. S., Patnode, C. D., Webber, E. M., Redmond, N., Rushkin, M., & O’Connor, E. A. (2018) · JAMA · doi:10.1001/jama.2018.7777 · Cited by 463
Medicinal strategies in the treatment of obesity
Bray, G. A., & Tartaglia, L. A. (2000) · Nature · doi:10.1038/35007544 · Cited by 432
Hickman, I. J., Jonsson, J. R., Prins, J. B., Ash, S., Purdie, D., Clouston, A. D., & Powell, E. E. (2004) · Gut · doi:10.1136/gut.2003.027581 · Cited by 438
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442
Zinke, I., Schütz, C. S., Katzenberger, J. D., Bauer, M. F., & Pankratz, M. J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf600 · Cited by 423
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 490
LeBlanc, E. S., O’Connor, E., Whitlock, E. P., Patnode, C. D., & Kapka, T. J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00006 · Cited by 409
“Orlistat was associated with a decrease in some fat-soluble vitamin levels compared with placebo (73, 74, 79, 82, 99).”
BackgroundResultBerkowitz, R. I., Wadden, T. A., Tershakovec, A. M., & Cronquist, J. L. (2003) · JAMA · doi:10.1001/jama.289.14.1805 · Cited by 389
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials
Mallinckrodt, C. H., Lane, P. W., Schnell, D. J., Peng, Y., & Mancuso, J. P. (2008) · Drug Information Journal · doi:10.1177/009286150804200402 · Cited by 358
“For example, in a weight maintenance study, patients who lose a substantial amount of body weight through nonpharmacological means begin drug therapy with the goal of maintaining the initial weight loss (33).”
Current and Potential Drugs for Treatment of Obesity
Bray, G. A., & Greenway, F. L. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0383 · Cited by 327
Ros, E. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00456-1 · Cited by 319
“[233] Hill JO, Hauptman J, Anderson JW, Fujioka K, O’Neil PM, Smith DK, Zavoral JH.”
BackgroundResultAntidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Current status of medical and surgical therapy for obesity
Mun, E. C., Blackburn, G. L., & Matthews, J. B. (2001) · Gastroenterology · doi:10.1053/gast.2001.22430 · Cited by 305
Orlistat: its current status as an anti-obesity drug
Ballinger, A., & Peikin, S. R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01422-x · Cited by 296
AGA technical review on obesity
Klein, S., Wadden, T., & Sugerman, H. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35514 · Cited by 274
Hudgel, D. W., Patel, S. R., Ahasic, A. M., Bartlett, S. J., Bessesen, D. H., Coaker, M. A., Fiander, P. M., Grunstein, R. R., Gurubhagavatula, I., Kapur, V. K., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1326st · Cited by 266
Randomized Clinical Trials of Weight Loss Maintenance: A Review
Turk, M. W., Yang, K., Hravnak, M., Sereika, S. M., Ewing, L. J., & Burke, L. E. (2009) · Journal of Cardiovascular Nursing · doi:10.1097/01.jcn.0000317471.58048.32 · Cited by 258
“Administering higher doses resulted in less regain.(62,63) In fact, Hill and colleagues(63) found that a higher proportion of the group participants who received orlistat 120 mg TID regained less than or equal to 25% of their body weight compared to that of the placebo group, P G .”
BackgroundLipases and lipolysis in the human digestive tract: where do we stand?
Armand, M. (2007) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3280177687 · Cited by 234
Yoshikawa, M., Shimoda, H., Matsuda, H., Nishida, N., & Takada, M. (2002) · Journal of Nutrition · doi:10.1093/jn/132.7.1819 · Cited by 233
“Reducing fat absorption is an effective way to suppress body weight gain, as seen in the clinical use of orlistat, a specific PL inhibitor, in obese patients (22).”
Background(SEEDO), S. E. P. E. E. D. L. O. (2000) · Medicina Clínica · doi:10.1016/s0025-7753(00)71632-0 · Cited by 232
Effects of Orlistat on Fat‐Soluble Vitamins in Obese Adolescents
McDuffie, J. R., Calis, K. A., Booth, S. L., Uwaifo, G. I., & Yanovski, J. A. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.11.814.33627 · Cited by 201
Feinle, C., O’Donovan, D., Doran, S., Andrews, J. M., Wishart, J. M., Chapman, I. M., & Horowitz, M. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00512.2002 · Cited by 197
“Therefore, it is possible that some patients taking THL increase their energy intake (28), although the latter has not been formally evaluated in these chronic studies (7, 25).”
BackgroundResultInfluentialLiu, D., Wang, F., Liao, T., Tang, J., Steglich, W., Zhu, H., & Liu, J. (2006) · Organic Letters · doi:10.1021/ol062307u · Cited by 189
Avenell, A., Brown, T. J., McGee, M. A., Campbell, M., GRANT, A. M., Broom, J. I., Jung, R. T., & Smith, W. C. (2004) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2004.00530.x · Cited by 186
“Studies where participants were randomized to treatments after a period of weight loss of 3 months or longer were classified as weight maintenance RCTs, e.g. the STORM trial (James et al., 2000) or the orlistat trial by Hill et al. (1999) and are not discussed here.”
MethodBehavioral treatment of obesity.
Kirkland, K., & Ct, M. (1983) · PubMed · Cited by 176
Pharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 169
“Weight maintenance with orlistat was evaluated in a 1-year study (Hill et al., 1999).”
BackgroundMethodInfluentialIoannides‐Demos, L. L., Proietto, J., & McNeil, J. J. (2005) · Drugs · doi:10.2165/00003495-200565100-00006 · Cited by 165
Zhang, L., Li, J., Hogan, S. P., Chung, H., Welbaum, G. E., & Zhou, K. (2009) · Food Chemistry · doi:10.1016/j.foodchem.2009.06.063 · Cited by 166
L Van Gaal for the ObelHyx Study Group, Muls, E., Kolanowski, J., Scheen, A. J., & Gaal, L. V. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801814 · Cited by 166
Obesity: An overview on its current perspectives and treatment options
Nammi, S., Koka, S., Chinnala, K. M., & Boini, K. M. (2004) · Nutrition Journal · doi:10.1186/1475-2891-3-3 · Cited by 174
Feinle, C., Rades, T., Otto, B., & Fried, M. (2001) · Gastroenterology · doi:10.1053/gast.2001.23232 · Cited by 152
Richelsen, B., Tonstad, S., Rössner, S., Toubro, S., NISKANEN, L. K., Madsbad, S., Mustajoki, P., & Rissanen, A. (2006) · Diabetes Care · doi:10.2337/dc06-0210 · Cited by 151
“The lipase inhibitor orlistat (Xenical) has been shown to promote additional weight loss compared with lifestyle modifications alone (10,11).”
BackgroundPharmacological Therapy of Obesity: Past, Present, and Future
Weigle, D. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030151 · Cited by 148
Management of Obesity as a Chronic Disease: Nonpharmacologic, Pharmacologic, and Surgical Options
Fujioka, K. (2002) · Obesity Research · doi:10.1038/oby.2002.204 · Cited by 146
Self-citationDiagnosis and Treatment of Obesity in Adults: An Applied Evidence-Based Review
Orzano, A. J., & Scott, J. G. (2004) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.17.5.359 · Cited by 145
Obesity: A Review of Pathogenesis and Management Strategies
Kaila, B., & Raman, M. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/609039 · Cited by 129
Pancreatic Lipase Inhibition by C-Glycosidic Flavones Isolated from Eremochloa ophiuroides
Lee, E. M., Lee, S. S., Chung, B. Y., Cho, J., Lee, I. C., Ahn, S. R., Jang, S. J., & Kim, T. H. (2010) · Molecules · doi:10.3390/molecules15118251 · Cited by 119
“The success of orlistat [5], which is a specific pancreatic lipase inhibitor, has prompted research to identify new pancreatic lipase inhibitors derived from natural sources, such as the constituents of Platycodin grandiflorum [6], Salvia officinalis [7], Salacia reticulate [8], and oolong tea [9].”
BackgroundHigh fat diet induces microbiota-dependent silencing of enteroendocrine cells
Ye, L., Mueller, O., Bagwell, J., Bagnat, M., Liddle, R. A., & Rawls, J. F. (2019) · eLife · doi:10.7554/elife.48479 · Cited by 120
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Arnold, M. E., & Steinberg, C. M. (2000) · Obesity Research · doi:10.1038/oby.2000.53 · Cited by 117
Obesity therapy: altering the energy intake-and-expenditure balance sheet
Crowley, V., Yeo, G. S. H., & O’Rahilly, S. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd770 · Cited by 116
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004096.pub2 · Cited by 113
Orlistat Inhibits Dietary Cholesterol Absorption
Mittendorfer, B., Ostlund, R. E., Patterson, B. W., & Klein, S. (2001) · Obesity Research · doi:10.1038/oby.2001.79 · Cited by 114
Anti-obesity drugs: a critical review of current therapies and future opportunities
Clapham, J. C. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00105-4 · Cited by 111
Sahebkar, A., Simental‐Mendía, L. E., Reiner, Ž., Kovanen, P. T., Simental-Mendía, M. A., Bianconi, V., & Pirro, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.022 · Cited by 110
Long-Term Weight Maintenance after an Intensive Weight-Loss Program
Anderson, J. W., Vichitbandra, S., Qian, W., & Kryscio, R. J. (1999) · Journal of the American College of Nutrition · doi:10.1080/07315724.1999.10718897 · Cited by 110
“We recently reported [36] that subjects given orlistat, a lipase inhibitor, enhanced weight maintenance over a one-year period after successful weight loss.”
BackgroundSelf-citationThe tumor microenvironment: shaping cancer progression and treatment response
Desai, S. A., Patel, V. P., Bhosle, K. P., Nagare, S. D., & Thombare, K. C. (2025) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2300224 · Cited by 106
Bray, G. A. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1011808701117 · Cited by 105
“Weight maintenance with orlistat was evaluated in a 1-year study [76].”
MethodLowe, M., Miller‐Kovach, K., & Phelan, S. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801521 · Cited by 105
A systematic review of the clinical effectiveness of orlistat used for the management of obesity
O'Meara, S., Riemsma, R., Shirran, L., Mather, L., & Ter Riet, G. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00125.x · Cited by 103
“(1999) (25) C: Placebo tid for 1 year (n = 188) N/R C: 68.”
BackgroundInfluentialHvizdos, K. M., & Markham, A. (1999) · Drugs · doi:10.2165/00003495-199958040-00015 · Cited by 101
“This was a consistent finding in all clinical trials reported to date.[28-32,34,37] Three trials[30,32,37] showed a significant decrease inLDL-C levels in orlistat versus placebo recipients coupled with relatively static high density lipoprotein-cholesterol (HDL-C) levels, resulting in a significant reduction in the L…”
InfluentialWeight management and current options in pharmacotherapy: Orlistat and sibutramine
Leung, W. Y. S., Thomas, G. N., Chan, J. C. N., & Tomlinson, B. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90009-9 · Cited by 98
Antiobesity action of ɛ-polylysine, a potent inhibitor of pancreatic lipase
Tsujita, T., Takaichi, H., Takaku, T., Aoyama, S., & Hiraki, J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600168-jlr200 · Cited by 97
Bakris, G. L., Calhoun, D. A., Egan, B. M., Hellmann, C. P., Dolker, M., & Kingma, I. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00026 · Cited by 96
Liu, W., Zheng, Y., Han, L.-K., Wang, H., Saito, M., Ling, M., Kimura, Y., & Feng, Y. (2008) · Phytomedicine · doi:10.1016/j.phymed.2008.07.002 · Cited by 95
Weight maintenance: challenges, tools and strategies for primary care physicians
Soleymani, T., Daniel, S., & Garvey, W. T. (2015) · Obesity Reviews · doi:10.1111/obr.12322 · Cited by 98
Orlistat in the treatment of obesity
Ballinger, A. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.841 · Cited by 91
Fabricatore, A. N., Wadden, T. A., Moore, R. H., Butryn, M. L., Gravallese, E. A., Erondu, N., Heymsfield, S. B., & Nguyen, A. M. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00567.x · Cited by 89
Tiikkainen, M., Bergholm, R., Rissanen, A., Aro, A., Salminen, I., Tamminen, M., Teramo, K., & Yki‐Järvinen, H. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.1.22 · Cited by 88
Zhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039062 · Cited by 84
“Among these included trials, 10 studies evaluated orlistat therapy [21–25,28,30,32–34], 3 [16,37,38] evaluated rimonabant therapy and remaining 8 [15,26,27,29,31,35,36,39] evaluated sibutramine therapy.”
BackgroundOrlistat: current status in clinical therapeutics
McClendon, K. S., Riche, D. M., & Uwaifo, G. I. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903321485 · Cited by 84
“There has in addition been one trial lasting ~ 1 year using orlistat for weight maintenance [57] and three 1-year trials of orlistat use in subjects with diabetes [19,20,58].”
BackgroundYuda, N., Tanaka, M., Suzuki, M., Asano, Y., Ochi, H., & Iwatsuki, K. (2012) · Journal of Food Science · doi:10.1111/j.1750-3841.2012.02967.x · Cited by 83
van Baak, M. A., van Mil, E., Astrup, A. V., Finer, N., Gaal, L. F. V., Hilsted, J., Kopelman, P. G., Rössner, S., James, W. P. T., & Saris, W. H. M. (2003) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.2.209 · Cited by 83
Pharmacological and surgical treatment of obesity.
Shekelle, P., Morton, S. C., Maglione, M., Suttorp, M. J., Tu, W., Li, Z., Maggard, M. A., Mojica, W., Shugarman, L. R., & Solomon, V. (2004) · PubMed · Cited by 80
Topiramate: A New Potential Pharmacological Treatment for Obesity*
Astrup, A. V., & Toubro, S. (2004) · Obesity Research · doi:10.1038/oby.2004.284 · Cited by 81
Combining Behavioral and Pharmacological Treatments for Obesity
Phelan, S., & Wadden, T. A. (2002) · Obesity Research · doi:10.1038/oby.2002.77 · Cited by 73
“(84) randomly assigned obese subjects who had lost �8% of their initial body weight (by diet and exercise alone) to placebo or orlistat, which was administered for 1 year in combination with a weight-maintenance diet.”
Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21140 · Cited by 72
“In addition, two studies using a similar study design demonstrated that, for individuals who achieved significant weight loss through low-calorie diets with no adjunct therapy, those who added orlistat (120 mg, three times daily) following weight loss regained significantly less weight over 1 year (91) or 3 years (92)…”
BackgroundScreening for anti-pancreatic lipase properties of 28 traditional Thai medicinal herbs
Dechakhamphu, A., & Wongchum, N. (2015) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2015.09.012 · Cited by 71
Cognitive and Behavioral Approaches in the Treatment of Obesity
Dorsten, B. V., & Lindley, E. M. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.008 · Cited by 75
Analysis of the Accuracy of Weight Loss Information Search Engine Results on the Internet
Modave, F. P., Shokar, N. K., Peñaranda, E., & Nguyen, N. (2014) · American Journal of Public Health · doi:10.2105/ajph.2014.302070 · Cited by 71
Karhunen, L. J., Franssila-Kallunki, A., Rissanen, P., Valve, R., Kolehmainen, M., Rissanen, A., & Uusitupa, M. I. J. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801443 · Cited by 71
Laaksonen, D. E., Laitinen, T. P., Schönberg, J., Rissanen, A., & NISKANEN, L. K. (2003) · Journal of Hypertension · doi:10.1097/00004872-200302000-00029 · Cited by 70
Bergholm, R., Tiikkainen, M., Vehkavaara, S., Tamminen, M., Teramo, K. A., Rissanen, A., & Yki‐Järvinen, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1667 · Cited by 70
“27 mmol/l in the placebo group, which is consistent with previous studies in obese women who have lost moderate amounts of weight (5–10%) (16).”
ResultSchroll, J. B., Penninga, E. I., & Gøtzsche, P. C. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002101 · Cited by 69
The effects of orlistat on metabolic parameters and other cardiovascular risk factors
Kiortsis, D. N., Filippatos, T. D., & Elisaf, M. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70161-1 · Cited by 68
“[28] evaluated the long-term effects of orlistat on obesity-related cardiovascular disease risk factors.”
BackgroundThe investigation and management of obesity
Labib, M. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.56.1.17 · Cited by 65
Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity
Chung, H., Yu, J. G., Lee, I., Liu, M., Shen, Y., Sharma, S. P., Jamal, M. A. H. M., Yoo, J., Kim, H., & Hong, S. (2015) · FEBS Open Bio · doi:10.1002/2211-5463.12024 · Cited by 68
Industry funding and the reporting quality of large long-term weight loss trials
Thomas, O., Thabane, L., Douketis, J. D., Chu, R., Westfall, A. O., & Allison, D. B. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.137 · Cited by 64
Ulen, C. G., Huizinga, M. M., Beech, B. M., & Elasy, T. A. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.3.100 · Cited by 60
A Functional Food Product for the Management of Weight
Bell, S. J., & Goodrick, G. K. (2002) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690290825501 · Cited by 60
Effect of NPY5R Antagonist MK‐0557 on Weight Regain after Very‐low‐calorie Diet‐induced Weight Loss
Erondu, N., Wadden, T. A., Gantz, I., Musser, B. J., Nguyen, A. M., Bays, H. E., Bray, G. A., O'Neil, P. M., Basdevant, A., Kaufman, K. D., et al. (2007) · Obesity · doi:10.1038/oby.2007.620 · Cited by 58
“(39) found that those who received orlistat (120 mg three times a day) for the ensuing year maintained a loss of 7.”
BackgroundSelf-citationObesity and Its Impact on Kidney Stone Formation.
Poore, W., Boyd, C. J., Singh, N. P., Wood, K. D., Gower, B. A., & Assimos, D. G. (2020) · PubMed Central · Cited by 55
Metadata
- Authors
- Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J.
- Affiliations
- Scripps Health (US)
- Corresponding author
- Aronne, Louis J
- Venue
- The American Journal of Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 1999-06
- Volume
- 69
- Issue
- 6
- Pages
- 1108-1116
- ISSN
- 0002-9165 (ISSN-L)
- OpenAlex
- W2166266400
- Cited by
- 287
- References
- 26
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 7 · 2014: 7 · 2013: 6 · 2012: 10
- FWCI
- 14.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- American Journal of Clinical Nutrition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- orlistat, lipase inhibitors, weight maintenance, weight regain, obesity, hypocaloric diet, long-term weight loss, LDL cholesterol, total cholesterol
- MeSH terms
- Orlistat, Adult, Behavior Therapy, Cardiovascular Diseases, Dietary Fats, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Lactones, Lipase, Cholesterol, HDL, Male, Obesity, Risk Factors, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
